Biocon and Mylan Launch Fulphila (biosimilar- pegfilgrastim) in Canada

Share this

Biocon and Mylan Launch Fulphila (biosimilar- pegfilgrastim) in Canada


  • The companies have launched Fulphila- a biosimilar referencing Neulasta (pegfilgrastim) and is approved by Health Canada to decrease the incidence of infection- as manifested by febrile neutropenia- in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs
  • The approval is based on analytical- non/clinical data- which showed that Fulphila is highly similar to Neulasta with no clinically meaningful differences in terms of safety and efficacy
  • The launch will expand biosimilar access to the patients in Canada- following the successful launch of Fulphila in the US. This is the second biosimilar to be launched in Canada under Mylan and Biocon collaboration

Click here ­to­ read full press release/ article | Ref: Biocon | Image: Mylan

Related News: Biocon and Mylan Launch Fulphila (biosimilar- Pegfilgrastim) in Australia

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions